Spectrum Pharmaceuticals Competitors and Similar CompaniesClear all
Spectrum Pharmaceuticals's competitors and similar companies include Halozyme Therapeutics, Immunome, Candel Therapeutics and Gerot Lannach.
 Spectrum Pharmaceuticals Spectrum Pharmaceuticals is a biotechnology company developing drugs to treat oncology and hematology. |  Halozyme Therapeutics Halozyme Therapeutics is a biotechnology company focused on developing and commercializing cancer therapies that target the tumor microenvironment. |  Immunome Immunome is a biotech company focused on cancer immunotherapies fueled by the human immune system. |  Candel Therapeutics Candel Therapeutics (formerly known as Advantagene) is a biopharmaceutical company developing cancer immunotherapies. |  Gerot Lannach Gerot Lannach is a pharmaceutical company that develops, produces, and sells both branded products and generics. | |
Founding Date | Founding Date 2002 | Founding Date 1998 | Founding Date 2008 | Founding Date 1999 | Founding Date 1947 |
Type | Type Public | Type Public | Type Public | Type Public | Type Private |
Tags | |||||
Locations | Locations Henderson, US HQ Irvine, US | Locations San Diego, US HQ | Locations Exton, US HQ | Locations Needham, US HQ | |
Employees | Employees 14638% decrease | Employees 373157% increase | Employees 264% decrease | Employees 50 | Employees 3401% increase |
Valuation ($) | Valuation ($) 211.4 m | Valuation ($) 6.4 b | Valuation ($) 746.5 m | Valuation ($) 176.8 m | Valuation ($) N/A |
Financial | |||||
Revenue (est.) | Revenue (est.) $10.1m (FY, 2022) | Revenue (est.) $1.4b (FY, 2025) | Revenue (est.) $6.9m (FY, 2025) | Revenue (est.) N/A | Revenue (est.) N/A |
Net income | Net income ($75.4m) (FY, 2022) | Net income $316.9m (FY, 2025) | Net income ($212.4m) (FY, 2025) | Net income ($38.2m) (FY, 2025) | Net income N/A |
Operating ⚠ | |||||
Phase I Trials Products | Phase I Trials Products 3 (FY, 2016) | Phase I Trials Products 10 (FY, 2020) | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A |
Phase II Trials Products | Phase II Trials Products 1 (FY, 2016) | Phase II Trials Products 1 (FY, 2020) | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A |
Phase III Trials Products | Phase III Trials Products 3 (FY, 2016) | Phase III Trials Products 8 (FY, 2020) | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A |
Funding | |||||
Total funding raised | Total funding raised $ 3m | Total funding raised $ 171.9m | Total funding raised $ 23.8m | Total funding raised $ 64.6m | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Halozyme Therapeutics
HQ
San Diego, US
Employees
373
Halozyme Therapeutics is a biotechnology company focused on developing and commercializing cancer therapies that target the tumor microenvironment.
View companyImmunome
HQ
Exton, US
Employees
26↓ 4% decrease
Immunome is a biotech company focused on cancer immunotherapies fueled by the human immune system.
View companyCandel Therapeutics
HQ
Needham, US
Employees
50
Candel Therapeutics (formerly known as Advantagene) is a biopharmaceutical company developing cancer immunotherapies.
View companyGerot Lannach
HQ
Lannach, AT
Employees
340↑ 1% increase
Gerot Lannach is a pharmaceutical company that develops, produces, and sells both branded products and generics.
View company